Compare Stocks: DNTH, MRNA, INCY, and BNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$116.57 +5.1%	$93.43	$79.52 ▼ $124.00	$29.48B	1.27	1.50 million shs	2.96 million shs
DNTH Dianthus Therapeutics	$111.10 +1.5%	$100.75	$22.76 ▼ $117.88	$6.07B	1.22	758,154 shs	730,872 shs
INCY Incyte	$127.81 +0.5%	$116.17	$81.09 ▼ $132.60	$25.91B	0.76	1.88 million shs	1.37 million shs
MRNA Moderna	$145.07 +8.8%	$68.49	$22.28 ▼ $176.66	$57.94B	0.91	19.88 million shs	87.10 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	+25.22%	+26.62%	+26.51%	+4.73%
DNTH Dianthus Therapeutics	0.00%	-4.19%	+6.02%	+28.47%	+374.38%
INCY Incyte	0.00%	+6.37%	+9.53%	+31.55%	+48.27%
MRNA Moderna	0.00%	+129.11%	+154.42%	+209.45%	+439.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$116.57 +5.1%	$93.43	$79.52 ▼ $124.00	$29.48B	1.27	1.50 million shs	2.96 million shs
DNTH Dianthus Therapeutics	$111.10 +1.5%	$100.75	$22.76 ▼ $117.88	$6.07B	1.22	758,154 shs	730,872 shs
INCY Incyte	$127.81 +0.5%	$116.17	$81.09 ▼ $132.60	$25.91B	0.76	1.88 million shs	1.37 million shs
MRNA Moderna	$145.07 +8.8%	$68.49	$22.28 ▼ $176.66	$57.94B	0.91	19.88 million shs	87.10 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	+25.22%	+26.62%	+26.51%	+4.73%
DNTH Dianthus Therapeutics	0.00%	-4.19%	+6.02%	+28.47%	+374.38%
INCY Incyte	0.00%	+6.37%	+9.53%	+31.55%	+48.27%
MRNA Moderna	0.00%	+129.11%	+154.42%	+209.45%	+439.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.74	Moderate Buy	$127.81	9.64% Upside
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$124.27	11.86% Upside
INCY Incyte	2.48	Hold	$123.10	-3.69% Downside
MRNA Moderna	2.00	Hold	$69.50	-52.09% Downside

Current Analyst Ratings Breakdown

Latest DNTH, MRNA, INCY, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$40.00 ➝ $77.00
8/20/2026	INCY Incyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$50.00 ➝ $150.00
8/20/2026	INCY Incyte	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$152.00
8/20/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$150.00
8/20/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$39.00 ➝ $89.00
8/19/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/19/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$67.00 ➝ $120.00
8/19/2026	MRNA Moderna	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$130.00
8/19/2026	MRNA Moderna	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$135.00
8/19/2026	MRNA Moderna	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	9.08	$1.34 per share	87.31	$81.64 per share	1.43
DNTH Dianthus Therapeutics	$2.04M	2,977.37	N/A	N/A	$21.44 per share	5.18
INCY Incyte	$5.14B	5.04	$6.18 per share	20.68	$31.30 per share	4.08
MRNA Moderna	$1.94B	29.79	N/A	N/A	$16.93 per share	8.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/4/2026 (Estimated)
INCY Incyte	$1.29B	$7.85	16.28	15.86	4.05	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)

Latest DNTH, MRNA, INCY, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
DNTH Dianthus Therapeutics	N/A	26.10	26.10
INCY Incyte	N/A	4.59	4.51
MRNA Moderna	0.09	2.29	2.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
DNTH Dianthus Therapeutics	47.53%
INCY Incyte	96.97%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
DNTH Dianthus Therapeutics	3.02%
INCY Incyte	16.20%
MRNA Moderna	10.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
DNTH Dianthus Therapeutics	80	54.67 million	53.02 million	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable

DNTH, MRNA, INCY, and BNTX Headlines

Recent News About These Companies

Heard on the Street: Moderna's mRNA cancer vaccine marks a major leap in personalized oncology. But the financial math is sobering.

August 23 at 5:30 AM | wsj.com

JPMorgan Chase & Co. Boosts Moderna (NASDAQ:MRNA) Price Target to $77.00

August 23 at 2:31 AM | americanbankingnews.com

Moderna (NASDAQ:MRNA) Sees Large Volume Increase Following Analyst Upgrade

August 23 at 1:41 AM | americanbankingnews.com

Why Moderna’s Cancer Vaccine Is a Breakthrough for mRNA

August 22 at 1:03 PM | bloomberg.com

Biotech Stocks To Add to Your Watchlist - August 22nd

August 22 at 1:00 PM | marketbeat.com

ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’

August 22 at 8:03 AM | stocktwits.comS

MarketBeat Week in Review – 08/17 - 08/21 (MRNA)

...

August 22 at 7:00 AM | marketbeat.com

Wealthfront Advisers LLC Purchases New Shares in Moderna, Inc. $MRNA

August 22 at 5:19 AM | marketbeat.com

Green Alpha Advisors LLC Buys Shares of 33,758 Moderna, Inc. $MRNA

August 22 at 4:08 AM | marketbeat.com

Morgan Stanley Boosts Moderna (NASDAQ:MRNA) Price Target to $89.00

August 22 at 1:54 AM | americanbankingnews.com

Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.

August 21 at 10:02 PM | finance.yahoo.com

Moderna, Merck Cancer Vax Gives Hope

August 21 at 10:02 PM | finance.yahoo.com

How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink

August 21 at 8:00 PM | wsj.com

MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week

August 21 at 6:00 PM | benzinga.com

Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players

August 21 at 5:01 PM | finance.yahoo.com

Healthcare Stocks To Follow Today - August 21st

August 21 at 1:01 PM | marketbeat.com

Moderna (NASDAQ:MRNA) Price Target Raised to $77.00 at JPMorgan Chase & Co.

August 21 at 12:23 PM | marketbeat.com

Biotech Stocks To Consider - August 21st

August 21 at 12:01 PM | marketbeat.com

Moderna’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod

August 21 at 12:00 PM | yahoo.com

Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session

August 21 at 12:00 PM | 247wallst.com

Moderna (NASDAQ:MRNA) Sees Strong Trading Volume on Analyst Upgrade

August 21 at 10:19 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DNTH, MRNA, INCY, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

$116.57 +5.68 (+5.12%)

As of 08/21/2026 04:00 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Dianthus Therapeutics NASDAQ:DNTH

$111.10 +1.59 (+1.45%)

As of 08/21/2026 04:00 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Incyte NASDAQ:INCY

$127.81 +0.59 (+0.46%)

As of 08/21/2026 04:00 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Moderna NASDAQ:MRNA

$145.07 +11.75 (+8.81%)

As of 08/21/2026 04:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DNTH, MRNA, INCY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DNTH, MRNA, INCY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DNTH, MRNA, INCY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DNTH, MRNA, INCY, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Dianthus Therapeutics NASDAQ:DNTH

Incyte NASDAQ:INCY

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DNTH, MRNA, INCY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DNTH, MRNA, INCY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DNTH, MRNA, INCY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DNTH, MRNA, INCY, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Dianthus Therapeutics NASDAQ:DNTH

Incyte NASDAQ:INCY

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools